而法学博士在网上查出来的药之一Amivantamab (Rybrevant)，加拿大肿瘤药物专家评审委员会的意见是在▶️治疗含铂化疗期间或之后进展给药◀️，且身体基础状况不能太差。

就是有药，她也不符合用药条件。

The CADTH pan-Canadian Oncology Drug Review Expert Review Committee (pERC) recommends that amivantamab be reimbursed for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy only if the conditions listed in Table 1 are met.

给药的具体条件是：癌症已扩散到其它部位 OR 已无法动手术， AND 病人已接受了含铂化疗；接受该靶向药物的病人健康状况相对良好。

Rybrevant（ 该药商品名）should only be covered to treat patients who have EGFR exon 20 insertion mutation–positive NSCLC that has spread to other parts of the body or cannot be removed by surgery, and who have already received treatment with a platinum-based chemotherapy. Patients receiving Rybrevant should be in relatively good health.